Nafarelin
Nafarelin acetate, RS-94991
Nafarelin is a synthetic decapeptide GnRH agonist distinguished by its bulky naphthylalanine substitution and by being delivered as a nasal spray rather than an injection. It is licensed for endometriosis, and in the United States also for central precocious puberty. Its pivotal trial against danazol in the late 1980s established GnRH agonists as a mainstream treatment for endometriosis.
Mechanism
Nafarelin replaces glycine at position 6 of native GnRH with 3-(2-naphthyl)-D-alanine, an unusually large, highly lipophilic aromatic residue in the D-configuration. This substitution serves two purposes at once. It sterically blocks the endopeptidase cleavage of the Gly6-Leu7 bond that terminates the action of endogenous GnRH within minutes, and the naphthyl group's lipophilicity substantially increases receptor binding affinity. Nafarelin is commonly cited as being of the order of 200 times more potent than native GnRH on a molar basis, though potency estimates depend heavily on the assay used. That potency matters practically, because it is what makes intranasal delivery viable despite the mucosa absorbing only a small percentage of each dose.
The pharmacodynamic consequence follows the agonist pattern. Twice-daily nasal administration maintains sufficient receptor occupancy to be effectively continuous rather than pulsatile. An initial gonadotrophin flare raises oestradiol for the first one to two weeks, followed by GnRH receptor downregulation and gonadotroph desensitisation, driving oestradiol into the postmenopausal range within about four weeks. In endometriosis this is the therapeutic goal: ectopic endometrial implants are oestrogen-dependent, and depriving them of oestradiol causes them to atrophy and reduces the associated pelvic pain. In central precocious puberty the same suppression halts premature pubertal progression, slows the accelerated skeletal maturation that would otherwise prematurely fuse the growth plates, and thereby preserves adult height potential.
What the research shows
The registration trial randomised women with laparoscopically confirmed endometriosis to intranasal nafarelin or oral danazol in a double-blind, double-dummy multicentre design. Both drugs produced comparable reductions in laparoscopically scored disease and in pelvic pain, but the adverse effect profiles differed in a way that favoured nafarelin for many patients: danazol, an attenuated androgen, caused weight gain, acne, oily skin, hirsutism and adverse lipid changes, whereas nafarelin's effects were those of oestrogen deprivation (hot flushes, vaginal dryness and headache). An independent randomised comparison by Kennedy and colleagues reached consistent conclusions. Together these trials moved GnRH agonists into mainstream endometriosis management.
The critical follow-up question was duration, since oestrogen deprivation causes bone loss. A prospective randomised double-blind trial compared three versus six months of nafarelin for endometriosis-associated pelvic pain and found that the shorter course produced broadly comparable symptom relief. This is an important and often overlooked result: it does not support extending treatment simply because symptoms recur, and it underpins the licensed six-month duration limit. The bone question is the honest weak point of the class. Vertebral bone mineral density falls measurably over six months of treatment, and while it largely recovers after discontinuation, recovery is not invariably complete. This is why repeat courses are approached cautiously and why hormonal add-back therapy is commonly used when longer treatment is unavoidable.
Evidence assessment
High-quality evidence
Nafarelin has held FDA and MHRA marketing authorisation since around 1990 and is supported by randomised controlled trials with active comparators, including a double-blind multicentre trial against danazol published in the New England Journal of Medicine and an independent randomised comparison in Fertility and Sterility. Duration of therapy was subsequently examined in a further prospective randomised double-blind trial. Regulator-approved labelling plus replicated randomised evidence places this firmly in the strong category. AUDIT NOTE: all three PMIDs verified against PubMed and each matches its stated title, journal and year.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial Preclinical only
Nafarelin and danazol produced comparable reductions in laparoscopic disease scores and pelvic pain. Adverse effects differed by mechanism: androgenic effects with danazol, hypo-oestrogenic effects with nafarelin. Established GnRH agonists as first-line medical therapy for endometriosis.
A comparison of nafarelin acetate and danazol in the treatment of endometriosis Preclinical only
Independent replication of comparable efficacy between nafarelin and danazol, with the divergent adverse effect profiles again favouring nafarelin in patients intolerant of androgenic side effects.
Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain Preclinical only
Three months of nafarelin gave broadly comparable pelvic pain relief to six months, arguing against routinely extending exposure and supporting the shortest effective course given the bone density cost.
Safety
The dominant adverse effects are those of induced hypo-oestrogenism: hot flushes in the large majority of women, vaginal dryness, headache, emotional lability, reduced libido, and decreased breast size. Loss of bone mineral density is the most consequential risk and is the reason licensed treatment is limited to six months in a single course; density largely but not always fully recovers after stopping. Because nafarelin is given nasally, local effects are common (nasal irritation, rhinitis and epistaxis), and absorption may be unpredictable during upper respiratory infection or if a topical nasal decongestant is used, potentially causing loss of suppression. Ovarian cysts may develop during the first two months, reflecting the initial flare. Nafarelin does not reliably prevent ovulation in the first weeks, so it must not be relied upon as contraception, and it is contraindicated in pregnancy. In children treated for precocious puberty, an initial transient increase in pubertal signs is expected. Rare cases of pituitary apoplexy after initiation have been reported.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Licensed prescription-only medicine (POM) regulated by the MHRA as a 2 mg/mL metered nasal spray delivering 200 micrograms per actuation. UK-licensed indications are the hormonal management of endometriosis and pituitary downregulation in controlled ovarian stimulation prior to in vitro fertilisation. Central precocious puberty is a United States indication and is not part of the current UK licence. |
| United States | Approved by the FDA around 1990. Prescription-only nasal solution, licensed for endometriosis and for central precocious puberty. Labelling limits a treatment course for endometriosis to six months because of bone loss. |
| WADA (sport) | Prohibited in male athletes at all times under section S2 of the WADA Prohibited List, which explicitly names nafarelin among gonadotrophin-releasing hormone agonist analogues. Not prohibited in female athletes. |
Questions
Its naphthylalanine substitution makes it far more potent than natural GnRH (commonly cited as roughly 200-fold), which is enough to overcome the poor absorption of the nasal route, where only about 2 to 3 per cent of each dose crosses the mucosa. The trade-off is twice-daily dosing and vulnerability to erratic absorption during a cold or when nasal decongestants are used.
Because oestrogen deprivation causes measurable loss of bone mineral density. The limit is a deliberate regulatory constraint balancing symptom relief against skeletal cost. Bone density largely recovers after stopping, but recovery is not always complete, so repeat courses are approached cautiously.
No, and this matters. During the initial flare and early weeks of treatment, ovulation is not reliably suppressed, so pregnancy remains possible. Nafarelin is contraindicated in pregnancy, so non-hormonal contraception is advised during treatment.
Frequently, yes. GnRH agonists suppress oestrogen-dependent disease rather than curing it, so endometriosis symptoms commonly recur once ovarian function returns. The randomised duration trial found extending treatment from three to six months did not clearly improve on this.